Uterine serous carcinoma and uterine carcinosarcoma: molecular features, clinical advances, and emerging therapies.
Clin Adv Hematol Oncol
; 22(6): 301-310, 2024.
Article
in En
| MEDLINE
| ID: mdl-39110653
ABSTRACT
Endometrial cancer, including high-grade subtypes, has a rising incidence and mortality. Uterine serous carcinoma (USC) and uterine carcinosarcoma (UCS) make up a small but increasing proportion of endometrial cancer cases and account for a significant portion of endometrial cancer mortality. Despite being molecularly and clinically distinct, both USC and UCS have a poor prognosis. Thus far, there have been few therapeutic strategies directed at these endometrial cancer subtypes. This review summarizes the genomic and molecular features of USC and UCS, clinical advances in the treatment of primary advanced and recurrent endometrial cancer, and novel molecularly-driven treatment strategies.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Uterine Neoplasms
/
Carcinosarcoma
/
Cystadenocarcinoma, Serous
Limits:
Female
/
Humans
Language:
En
Journal:
Clin Adv Hematol Oncol
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
Year:
2024
Document type:
Article
Country of publication:
Estados Unidos